Literature DB >> 21110092

Systemic mastocytosis presenting with acute oliguric renal failure: report of a case and review of the literature.

Ann E Moore1, William H Johnston, Aviv Hever, Susy Peng, Dean A Kujubu.   

Abstract

A 61-year old African-American woman presented with abdominal pain, tender splenomegaly, anemia, and renal insufficiency. Bone marrow biopsy demonstrated systemic mastocytosis. She was treated with mediator-specific therapy and imatinib, but her renal and hepatic function deteriorated and she required maintenance hemodialysis. Renal biopsy demonstrated interstitial infiltration with mast cells and acute tubular necrosis. Acute kidney injury in the setting of systemic mastocytosis and imatinib therapy is discussed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21110092     DOI: 10.1007/s11255-010-9878-5

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  9 in total

Review 1.  Systemic mastocytosis.

Authors:  Cem Akin; Dean D Metcalfe
Journal:  Annu Rev Med       Date:  2004       Impact factor: 13.739

2.  Response to interferon alfa-2b in a patient with systemic mastocytosis.

Authors:  H C Kluin-Nelemans; J H Jansen; H Breukelman; B G Wolthers; P M Kluin; H M Kroon; R Willemze
Journal:  N Engl J Med       Date:  1992-02-27       Impact factor: 91.245

3.  [Acute kidney failure revealing mastocytosis].

Authors:  A Talaszka; E Boulanger; H Le Monies de Sagazan; C Le Blan
Journal:  Presse Med       Date:  1992-05-23       Impact factor: 1.228

4.  Tumour lysis syndrome with acute renal failure during imatinib therapy.

Authors:  Ridvan Ali; Fahir Ozkalemkas; Atilla Ozkan; Tulay Ozcelik; Vildan Ozkocaman; Ibrahim Akdag; Ulku Ozan; Ahmet Tunali
Journal:  Leuk Res       Date:  2006-06-16       Impact factor: 3.156

Review 5.  Clonality and molecular pathogenesis of mastocytosis.

Authors:  Cem Akin
Journal:  Acta Haematol       Date:  2005       Impact factor: 2.195

6.  Acute renal failure secondary to imatinib mesylate treatment in prostate cancer.

Authors:  John R Foringer; Regina R Verani; Vincent M Tjia; Kevin W Finkel; Joshua A Samuels; Jayarama S Guntupalli
Journal:  Ann Pharmacother       Date:  2005-11-15       Impact factor: 3.154

7.  The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations.

Authors:  Yongsheng Ma; Shan Zeng; Dean D Metcalfe; Cem Akin; Sasa Dimitrijevic; Joseph H Butterfield; Gerald McMahon; B Jack Longley
Journal:  Blood       Date:  2002-03-01       Impact factor: 22.113

8.  Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia.

Authors:  Monica Pou; Nuria Saval; Manel Vera; Anna Saurina; Manel Solé; Francisco Cervantes; Albert Botey
Journal:  Leuk Lymphoma       Date:  2003-07

9.  Renal involvement in lymphoma: prevalence and various patterns of involvement on abdominal CT.

Authors:  Mohammed Sherif El-Sharkawy; Neelam Siddiqui; Aamer Aleem; Abdulrahman Al Diab
Journal:  Int Urol Nephrol       Date:  2007-06-05       Impact factor: 2.370

  9 in total
  2 in total

1.  Indolent systemic mastocytosis associated with light chain deposition disease.

Authors:  Kotaro Sasaki; Alice Chang; Behzad Najafian
Journal:  Clin Kidney J       Date:  2012-10

2.  Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature.

Authors:  Iván Alvarez-Twose; Almudena Matito; José Mário Morgado; Laura Sánchez-Muñoz; María Jara-Acevedo; Andrés García-Montero; Andrea Mayado; Carolina Caldas; Cristina Teodósio; Javier Ignacio Muñoz-González; Manuela Mollejo; Luis Escribano; Alberto Orfao
Journal:  Oncotarget       Date:  2016-07-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.